Natural Product (NP) Details

General Information of the NP (ID: NP5651)
Name
Morusin
Synonyms
Morusin; 62596-29-6; Mulberrochromene; TCMDC-124149; UNII-T4VGD5NP9B; NSC649220; T4VGD5NP9B; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one; CHEBI:7005; CHEMBL464006; 2-(2,4-Dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-en-1-yl)pyrano[2,3-f]chromen-4(8H)-one; 4H,8H-Benzo(1,2-b:3,4-b')dipyran-4-one, 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-; Morusin, 3; NSC 649220; MLS000697591; MEGxp0_001039; SCHEMBL2562778; ACon1_001205; cid_5281671; DTXSID70211641; HMS2271K05; BCP16494; HY-N0622; ZINC5195808; BDBM50242014; LMPK12110912; MFCD09953814; AKOS032962066; CS-6885; NSC-649220; AK169967; LS-15105; SMR000470930; FT-0686661; N2266; W1523; A14647; C10106; BRD-K40169295-001-01-2; Q27107393; 2-(2,4-dihydroxyphenyl)-5-hydroxy-3-(3-methyl-2-butenyl)-4H-6,6-dimethylpyrano- [2,3-h]-1-benzopyran-4-one; 2-(2,4-Dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one; 2-(2,4-Dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one, 9CI; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-en-1-yl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one
    Click to Show/Hide
Species Origin Morus australis ...     Click to Show/Hide
Morus australis
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Rosales
Family: Moraceae
Genus: Morus
Species: Morus australis
Disease Renal cell carcinoma [ICD-11: 2C90] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -5.119
 
MDCK Permeability
 -4.772
 
PAMPA
 -
 
HIA
 - - -
 
Distribution
VDss
 0.454
 
PPB
 96.1%
 
BBB
 - - -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 +++
CYP2C19 substrate
 +++
CYP2C9 inhibitor
 +++
CYP2C9 substrate
 - -
CYP2D6 inhibitor
 ++
CYP2D6 substrate
 -
CYP3A4 inhibitor
 ++
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 +++
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 +++
HLM Stability
 +++
 
Excretion
CLplasma
 1.671
 
T1/2
 1.734
Toxicity
DILI
 ++
 
Rat Oral Acute Toxicity
 ++
 
FDAMDD
 ++
 
Respiratory
 +++
 
Human Hepatotoxicity
 -
 
Ototoxicity
 - -
 
Drug-induced Nephrotoxicity
 - -
 
Drug-induced Neurotoxicity
 - -
 
Hematotoxicity
 - - -
 
Genotoxicity
 +++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C25H24O6
PubChem CID
5281671
Canonical SMILES
CC(=CCC1=C(OC2=C(C1=O)C(=CC3=C2C=CC(O3)(C)C)O)C4=C(C=C(C=C4)O)O)C
InChI
1S/C25H24O6/c1-13(2)5-7-17-22(29)21-19(28)12-20-16(9-10-25(3,4)31-20)24(21)30-23(17)15-8-6-14(26)11-18(15)27/h5-6,8-12,26-28H,7H2,1-4H3
InChIKey
XFFOMNJIDRDDLQ-UHFFFAOYSA-N
CAS Number
CAS 62596-29-6
ChEBI ID
CHEBI:7005
Herb ID
HBIN035791
SymMap ID
SMIT00422
TCMSP ID
MOL000739
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP
          TNF-related apoptosis inducing ligand      Lung cancer     Click to Show/Hide the Molecular Data of This Drug
                 Decreasing Adverse Drug Reaction     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression TRAIL-R2  Molecule Info 
Pathway MAP
                    In-vitro Model U-251MG CVCL_0021 Astrocytoma Homo sapiens
LN-18 CVCL_0392 Glioblastoma Homo sapiens
                    Experimental
                    Result(s)		 Morusin induces TRAIL sensitization by regulating EGFR and DR5 in human glioblastoma cells.
Target and Pathway
Target(s) CCAAT/enhancer binding beta (CEBPB)  Molecule Info  [3]
PPAR-gamma (PPARG)  Molecule Info  [3]
KEGG Pathway PPAR signaling pathway Click to Show/Hide
2 AMPK signaling pathway
3 Osteoclast differentiation
4 Huntington's disease
5 Pathways in cancer
6 Transcriptional misregulation in cancer
7 Thyroid cancer
8 TNF signaling pathway
9 Tuberculosis
NetPath Pathway IL1 Signaling Pathway Click to Show/Hide
2 TGF_beta_Receptor Signaling Pathway
3 Leptin Signaling Pathway
4 IL4 Signaling Pathway
Panther Pathway CCKR signaling map ST Click to Show/Hide
Pathway Interaction Database Noncanonical Wnt signaling pathway Click to Show/Hide
2 Calcineurin-regulated NFAT-dependent transcription in lymphocytes
3 Signaling events mediated by HDAC Class I
4 RXR and RAR heterodimerization with other nuclear receptor
5 Regulation of retinoblastoma protein
6 Regulation of nuclear SMAD2/3 signaling
7 IL4-mediated signaling events
8 FOXA2 and FOXA3 transcription factor networks
9 IFN-gamma pathway
10 IL3-mediated signaling events
11 IL6-mediated signaling events
12 C-MYB transcription factor network
13 Validated nuclear estrogen receptor alpha network
14 Signaling mediated by p38-alpha and p38-beta
15 FOXA1 transcription factor network
Reactome PPARA activates gene expression Click to Show/Hide
2 Transcriptional regulation of white adipocyte differentiation
3 Nuclear Receptor transcription pathway
4 Senescence-Associated Secretory Phenotype (SASP)
WikiPathways Wnt Signaling Pathway Netpath Click to Show/Hide
2 Nuclear Receptors in Lipid Metabolism and Toxicity
3 Differentiation of white and brown adipocyte
4 Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
5 Transcriptional Regulation of White Adipocyte Differentiation
6 Adipogenesis
7 SREBP signalling
8 Nuclear Receptors
9 SIDS Susceptibility Pathways
10 Senescence and Autophagy in Cancer
11 Diurnally Regulated Genes with Circadian Orthologs
12 IL-4 Signaling Pathway
13 Ovarian Infertility Genes
14 Transcriptional activation by NRF2
15 Oncostatin M Signaling Pathway
16 IL17 signaling pathway
17 miR-targeted genes in muscle cell - TarBase
18 miR-targeted genes in lymphocytes - TarBase
19 miR-targeted genes in leukocytes - TarBase
20 miR-targeted genes in epithelium - TarBase
21 miR-targeted genes in adipocytes - TarBase
22 Folate-Alcohol and Cancer Pathway
References
Reference 1 Morusin exerts anti-cancer activity in renal cell carcinoma by disturbing MAPK signaling pathways. Ann Transl Med. 2020 Mar;8(6):327.
Reference 2 Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells. J Nat Prod. 2016 Feb 26;79(2):317-23.
Reference 3 Morusin suppresses breast cancer cell growth in vitro and in vivo through C/EBPBeta and PPARGamma mediated lipoapoptosis. J Exp Clin Cancer Res. 2015 Nov 4;34:137.
 Download Picture         KEGG Link